How we improved the treatment of Hodgkin lymphoma

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Hodgkin lymphoma has long been a model disease in the field of oncology—one of the first diseases we learned to cure with radiation and ultimately chemotherapy. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Alex Herrera, MD
Chief, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope Los Angeles
Table of Contents

YOU MAY BE INTERESTED IN

The recent ASCO guideline update on palliative care for cancer patients represents a significant milestone in our field’s evolution. This evidence-based guidance emphasizes what I’ve advocated throughout my career—that palliative care must be integrated early and concurrently throughout the cancer journey. This holistic approach to cancer care has been my life’s work and passion. 
The Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for the extension of the marketing authorization of Adcetris (brentuximab vedotin) and recommended its approval in combination with etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone, a chemotherapy regimen, in adult patients with newly diagnosed stage 2b with risk factors/3/4 Hodgkin lymphoma.
Alex Herrera, MD
Chief, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope Los Angeles

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login